These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. Sung J; Espiritu JI; Segall GM; Terris MK BJU Int; 2003 Jul; 92(1):24-7. PubMed ID: 12823377 [TBL] [Abstract][Full Text] [Related]
6. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Shreve PD; Grossman HB; Gross MD; Wahl RL Radiology; 1996 Jun; 199(3):751-6. PubMed ID: 8638000 [TBL] [Abstract][Full Text] [Related]
7. Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans. Kang PM; Seo WI; Lee SS; Bae SK; Kwak HS; Min K; Kim W; Kang DI Asian Pac J Cancer Prev; 2014; 15(20):8699-703. PubMed ID: 25374193 [TBL] [Abstract][Full Text] [Related]
8. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions. Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363 [TBL] [Abstract][Full Text] [Related]
9. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide? Vargas HA; Martin-Malburet AG; Takeda T; Corradi RB; Eastham J; Wibmer A; Sala E; Zelefsky MJ; Weber WA; Hricak H Urol Oncol; 2016 Nov; 34(11):482.e5-482.e10. PubMed ID: 27346339 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases. Chang CY; Gill CM; Joseph Simeone F; Taneja AK; Huang AJ; Torriani M; Bredella MA Acta Radiol; 2016 Jan; 57(1):58-65. PubMed ID: 25533313 [TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Fricke E; Machtens S; Hofmann M; van den Hoff J; Bergh S; Brunkhorst T; Meyer GJ; Karstens JH; Knapp WH; Boerner AR Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):607-11. PubMed ID: 12589476 [TBL] [Abstract][Full Text] [Related]
13. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853 [TBL] [Abstract][Full Text] [Related]
14. Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. Wu SL; Jones E; Gulley JL; Arlen PM; Chen CC; Figg WD; Dahut WL BJU Int; 2007 Mar; 99(3):525-8. PubMed ID: 17155971 [TBL] [Abstract][Full Text] [Related]
15. Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Chang CH; Wu HC; Tsai JJ; Shen YY; Changlai SP; Kao A Urol Int; 2003; 70(4):311-5. PubMed ID: 12740497 [TBL] [Abstract][Full Text] [Related]
16. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Pandit-Taskar N; O'Donoghue JA; Durack JC; Lyashchenko SK; Cheal SM; Beylergil V; Lefkowitz RA; Carrasquillo JA; Martinez DF; Fung AM; Solomon SB; Gönen M; Heller G; Loda M; Nanus DM; Tagawa ST; Feldman JL; Osborne JR; Lewis JS; Reuter VE; Weber WA; Bander NH; Scher HI; Larson SM; Morris MJ Clin Cancer Res; 2015 Dec; 21(23):5277-85. PubMed ID: 26175541 [TBL] [Abstract][Full Text] [Related]
17. Detection of a second malignancy in prostate cancer patients by using [(18)F]Choline PET/CT: a case series. Sollini M; Pasqualetti F; Perri M; Coraggio G; Castellucci P; Roncali M; Boni R; Lazzeri E; Galeandro M; Paiar F; Versari A; Erba PA Cancer Imaging; 2016 Aug; 16(1):27. PubMed ID: 27581366 [TBL] [Abstract][Full Text] [Related]
18. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG. Nakamoto Y; Osman M; Wahl RL Clin Nucl Med; 2003 Apr; 28(4):302-7. PubMed ID: 12642709 [TBL] [Abstract][Full Text] [Related]
19. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Schöder H; Herrmann K; Gönen M; Hricak H; Eberhard S; Scardino P; Scher HI; Larson SM Clin Cancer Res; 2005 Jul; 11(13):4761-9. PubMed ID: 16000572 [TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography and bone metastases. Fogelman I; Cook G; Israel O; Van der Wall H Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]